


BioInvent

Treatment of atherosclerosis: secondary prevention of acute myocardial infarction.



Molecule:

BI-204 is a human antibody which targets the oxidised form of a low-density lipoprotein (LDL), called apoB100.

Intellectual property:

Genentech obtained the commercialisation rights for North America in 2008. BioInvent has retained the rights for the rest of the world.

Unmet needs and Target group:

Currently there are no effective medications for people who have already suffered a heart attack and are at increased risk of experiencing a cardiovascular event. This targets over 15 million people in the five major pharmaceutical markets alone.

Market:

“Cardiovascular Pharmaceutical Market Trends 2007 to 2010 - Key Market Forecasts and Growth Opportunities” reports that the global cardiovascular market is forecast to expand to US \$116 billion in 2010

Development stage and Suggested treatment:

A Phase I trial of BI-204 has been completed. Preclinical studies showed that administering BI-204 could substantially reduce the formation of atherosclerotic plaques by over 50%. The drug also reduced the size of plaques already present by 50% over four weeks.

Contact:

Dr. Bert Junno, Lund University Technology Group, +46-707-772209, bert.junno@forskarpatent.com

Dr. Mikael Lindstam, Lund University Technology Group, +46-766-333699, mikael.lindstam@forskarpatent.com